N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies

1.

Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46:D303–d07. https://doi.org/10.1093/nar/gkx1030.CrossRefPubMed

2.

Wang X, Li Y, Chen W, Shi H, Eren AM, Morozov A, et al. Transcriptome-wide reprogramming of N (6)-methyladenosine modification by the mouse microbiome. Cell Res. 2019;29:167–70. https://doi.org/10.1038/s41422-018-0127-2.CrossRefPubMed

3.

Lichinchi G, Gao S, Saletore Y, Gonzalez GM, Bansal V, Wang Y, et al. Dynamics of the human and viral m (6) A RNA methylomes during HIV-1 infection of T cells. Nature Microbiol. 2016;1:16011. https://doi.org/10.1038/nmicrobiol.2016.11.CrossRef

4.

Du C, Lv C, Feng Y, Yu S. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exper Clin Cancer Res. 2020;39:223. https://doi.org/10.1186/s13046-020-01735-3.CrossRef

5.

Zhu S, Wang JZ, Chen D, He YT, Meng N, Chen M, et al. An oncopeptide regulates m (6) A recognition by the m (6) A reader IGF2BP1 and tumorigenesis. Nature Commun. 2020;11:1685. https://doi.org/10.1038/s41467-020-15403-9.CrossRef

6.

Huang R, Zhang Y, Bai Y, Han B, Ju M, Chen B, et al. N (6)-Methyladenosine modification of fatty acid amide hydrolase messenger RNA in circular RNA STAG1-regulated astrocyte dysfunction and depressive-like behaviors. Biol Psychiatry. 2020;88:392–404. https://doi.org/10.1016/j.biopsych.2020.02.018.CrossRefPubMed

7.

Gao XQ, Zhang YH, Liu F, Ponnusamy M, Zhao XM, Zhou LY, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N (6)-methyladenosine methylation of Parp10 mRNA. Nature Cell Biol. 2020;22:1319–31. https://doi.org/10.1038/s41556-020-0576-y.CrossRefPubMed

8.

Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2020. https://doi.org/10.1182/blood.2019003764.

9.

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6. https://doi.org/10.1038/nature11112.CrossRefPubMed

10.

Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635–46. https://doi.org/10.1016/j.cell.2012.05.003.CrossRefPubMedPubMedCentral

11.

Garcia-Campos MA, Edelheit S, Toth U, Safra M, Shachar R, Viukov S, et al. Deciphering the “m (6) A Code” via Antibody-Independent Quantitative Profiling. Cell. 2019;178:731–47.e16. https://doi.org/10.1016/j.cell.2019.06.013.CrossRefPubMed

12.

Zhang Z, Chen LQ, Zhao YL, Yang CG, Roundtree IA, Zhang Z, et al. Single-base mapping of m (6) A by an antibody-independent method. Sci Adv. 2019;5:eaax0250. https://doi.org/10.1126/sciadv.aax0250.CrossRefPubMedPubMedCentral

13.

Wang Y, Xiao Y, Dong S, Yu Q, Jia G. Antibody-free enzyme-assisted chemical approach for detection of N (6)-methyladenosine. Nat Chem Biol. 2020. https://doi.org/10.1038/s41589-020-0525-x.

14.

Shu X, Cao J, Cheng M, Xiang S, Gao M, Li T, et al. A metabolic labeling method detects m (6) A transcriptome-wide at single base resolution. Nat Chem Biol. 2020. https://doi.org/10.1038/s41589-020-0526-9.

15.

Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018;46:5195–208. https://doi.org/10.1093/nar/gky156.CrossRefPubMedPubMedCentral

16.

Sun HL, Zhu AC, Gao Y, Terajima H, Fei Q, Liu S, et al. Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m (6) A Methylation. Mol Cell. 2020;80:633–47.e7. https://doi.org/10.1016/j.molcel.2020.10.026.CrossRefPubMedPubMedCentral

17.

Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016;63:306–17. https://doi.org/10.1016/j.molcel.2016.05.041.CrossRefPubMedPubMedCentral

18.

Wang Z, Pan Z, Adhikari S, Harada BT, Shen L, Yuan W, et al. m (6) A deposition is regulated by PRMT1-mediated arginine methylation of METTL14 in its disordered C-terminal region. EMBO J. 2021:e106309. https://doi.org/10.15252/embj.2020106309.

19.

Peng F, Xu J, Cui B, Liang Q, Zeng S, He B, et al. Oncogenic AURKA-enhanced N (6)-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2020. https://doi.org/10.1038/s41422-020-00397-2.

20.

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N-6-adenosine methylation. Nat Chem Biol. 2014;10:93–5. https://doi.org/10.1038/nchembio.1432.CrossRefPubMed

21.

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, et al. VIRMA mediates preferential m (6) A mRNA methylation in 3 ‘ UTR and near stop codon and associates with alternative polyadenylation. Cell Discovery. 2018;4. https://doi.org/10.1038/s41421-018-0019-0.

22.

Wen J, Lv R, Ma H, Shen H, He C, Wang J, et al. Zc3h13 Regulates Nuclear RNA m (6) A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Mol Cell. 2018;69:1028. https://doi.org/10.1016/j.molcel.2018.02.015.CrossRefPubMedPubMedCentral

23.

Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, Hobartner C, et al. Human METTL16 is a N (6)-methyladenosine (m (6) A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017;18:2004–14. https://doi.org/10.15252/embr.201744940.CrossRefPubMedPubMedCentral

24.

Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, et al. The U6 snRNA m (6) A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention. Cell. 2017;169:824. https://doi.org/10.1016/j.cell.2017.05.003.CrossRefPubMedPubMedCentral

25.

Mikutis S, Gu M, Sendinc E, Hazemi ME, Kiely-Collins H, Aspris D, et al. meCLICK-Seq, a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Sci. 2020;6:2196–208. https://doi.org/10.1021/acscentsci.0c01094.CrossRef

26.

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7. https://doi.org/10.1038/nchembio.687.CrossRefPubMedPubMedCentral

27.

Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, et al. Reversible methylation of m (6) A (m) in the 5′ cap controls mRNA stability. Nature. 2017;541:371–5. https://doi.org/10.1038/nature21022.CrossRefPubMed

28.

Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798. https://doi.org/10.1038/ncomms2822.CrossRefPubMed

29.

Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, et al. Differential m (6) A, m (6) A(m), and m (1) A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell. 2018;71:973–85.e5. https://doi.org/10.1016/j.molcel.2018.08.011.CrossRefPubMedPubMedCentral

30.

Liu X, Liu J, Xiao W, Zeng Q, Bo H, Zhu Y, et al. SIRT1 Regulates N (6) -Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2-Dependent FTO SUMOylation. Hepatology (Baltimore, Md). 2020;72:2029–50. https://doi.org/10.1002/hep.31222.CrossRef

31.

Song W, Yang K, Luo J, Gao Z, Gao Y. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression. Aging. 2021;13:3909–25. https://doi.org/10.18632/aging.202359.CrossRefPubMedPubMedCentral

32.

Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Molecular cell. 2013;49:18–29. https://doi.org/10.1016/j.molcel.2012.10.015.CrossRefPubMed

33.

Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, et al. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021. https://doi.org/10.1093/nar/gkab065.

34.

Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12:177. https://doi.org/10.1038/s41467-020-20379-7.CrossRefPubMedPubMedCentral

35.

Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, et al. FBW7 suppresses ovarian cancer development by targeting the N (6)-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20:45. https://doi.org/10.1186/s12943-021-01340-8.CrossRefPubMedPubMedCentral

36.

Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N-6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117. https://doi.org/10.1038/nature12730.CrossRefPubMed

37.

Zhuang M, Li X, Zhu J, Zhang J, Niu F, Liang F, et al. The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. Nucleic Acids Res. 2019;47:4765–77. https://doi.org/10.1093/nar/gkz157.CrossRefPubMedPubMedCentral

38.

Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, et al. YTHDF3 facilitates translation and decay of N (6)-methyladenosine-modified RNA. Cell Res. 2017;27:315–28. https://doi.org/10.1038/cr.2017.15.CrossRefPubMedPubMedCentral

39.

Zaccara S, Jaffrey SR. A Unified Model for the Function of YTHDF Proteins in Regulating m (6) A-Modified mRNA. Cell. 2020;181:1582–95.e18. https://doi.org/10.1016/j.cell.2020.05.012.CrossRefPubMedPubMedCentral

40.

Zhang Z, Luo K, Zou Z, Qiu M, Tian J, Sieh L, et al. Genetic analyses support the contribution of mRNA N (6)-methyladenosine (m (6) A) modification to human disease heritability. Nat Genet. 2020. https://doi.org/10.1038/s41588-020-0644-z.

41.

Xiao W, Adhikari S, Dahal U, Chen Y-S, Hao Y-J, Sun B-F, et al. Nuclear m (6) A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61:507–19. https://doi.org/10.1016/j.molcel.2016.01.012.CrossRefPubMed

42.

Roundtree IA, Luo G-Z, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 mediates nuclear export of N-6 - methyladenosine methylated mRNAs. Elife. 2017;6. https://doi.org/10.7554/eLife.31311.

43.

Liu J, Dou X, Chen C, Chen C, Liu C, Xu MM, et al. N (6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science (New York, NY). 2020;367:580–6. https://doi.org/10.1126/science.aay6018.CrossRef

44.

Kretschmer J, Rao H, Hackert P, Sloan KE, Höbartner C, Bohnsack MT. The m (6) A reader protein YTHDC2 interacts with the small ribosomal subunit and the 5′-3′ exoribonuclease XRN1. RNA (New York, NY). 2018;24:1339–50. https://doi.org/10.1261/rna.064238.117.CrossRef

45.

Mao Y, Dong L, Liu XM, Guo J, Ma H, Shen B, et al. m (6) A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2. Nat Commun. 2019;10:5332. https://doi.org/10.1038/s41467-019-13317-9.CrossRefPubMedPubMedCentral

46.

Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N (6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27:1115–27. https://doi.org/10.1038/cr.2017.99.CrossRefPubMedPubMedCentral

47.

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N-6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518:560–4. https://doi.org/10.1038/nature14234.CrossRefPubMedPubMedCentral

48.

Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPA2B1 is a mediator of m (6) A-dependent nuclear RNA processing events. Cell. 2015;162:1299–308. https://doi.org/10.1016/j.cell.2015.08.011.CrossRefPubMedPubMedCentral

49.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N-6- methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285. https://doi.org/10.1038/s41556-018-0045-z.CrossRefPubMedPubMedCentral

50.

Edens BM, Vissers C, Su J, Arumugam S, Xu Z, Shi H, et al. FMRP Modulates Neural Differentiation through m (6) A-Dependent mRNA Nuclear Export. Cell Rep. 2019;28:845–54.e5. https://doi.org/10.1016/j.celrep.2019.06.072.CrossRefPubMedPubMedCentral

51.

Fan C, Tu C, Qi P, Guo C, Xiang B, Zhou M, et al. GPC6 promotes cell proliferation, migration, and invasion in nasopharyngeal carcinoma. J Cancer. 2019;10:3926–32. https://doi.org/10.7150/jca.31345.CrossRefPubMedPubMedCentral

52.

Mo Y, Wang Y, Xiong F, Ge X, Li Z, Li X, et al. Proteomic analysis of the molecular mechanism of lovastatin inhibiting the growth of nasopharyngeal carcinoma cells. J Cancer. 2019;10:2342–9. https://doi.org/10.7150/jca.30454.CrossRefPubMedPubMedCentral

53.

Wang D, Zeng Z, Zhang S, Xiong F, He B, Wu Y, et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell proliferation through the LOC553103-STMN1 axis. FASEB J. 2020;34:8012–27. https://doi.org/10.1096/fj.202000039RR.CrossRefPubMed

54.

Hirayama M, Wei FY, Chujo T, Oki S, Yakita M, Kobayashi D, et al. FTO Demethylates Cyclin D1 mRNA and controls cell-cycle progression. Cell Rep. 2020;31:107464. https://doi.org/10.1016/j.celrep.2020.03.028.CrossRefPubMed

55.

Yang Z, Wang T, Wu D, Min Z, Tan J, Yu B. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exper Clin Cancer Res. 2020;39:203. https://doi.org/10.1186/s13046-020-01714-8.CrossRef

56.

Gao S, Gu Y, Niu S, Wang Y, Duan L, Pan Y, et al. DMDRMR-mediated regulation of m6A-modified CDK4 by m6A reader IGF2BP3 drives ccRCC progression. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.Can-20-1619.

57.

Zhu W, Si Y, Xu J, Lin Y, Wang JZ, Cao M, et al. Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner. J Cell Mol Med. 2020;24:3521–33. https://doi.org/10.1111/jcmm.15042.CrossRefPubMedPubMedCentral

58.

Tassinari V, Cesarini V, Tomaselli S, Ianniello Z, Silvestris DA, Ginistrelli LC, et al. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021;22:51. https://doi.org/10.1186/s13059-021-02271-9.CrossRefPubMedPubMedCentral

59.

Müller S, Bley N, Busch B, Glaß M, Lederer M, Misiak C, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 2020;48:8576–90. https://doi.org/10.1093/nar/gkaa653.CrossRefPubMedPubMedCentral

60.

Chen Y, Peng C, Chen J, Chen D, Yang B, He B, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18:127. https://doi.org/10.1186/s12943-019-1053-8.CrossRefPubMedPubMedCentral

61.

Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 2020;19:91. https://doi.org/10.1186/s12943-020-01158-w.CrossRefPubMedPubMedCentral

62.

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m (6) A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019;38:3667–80. https://doi.org/10.1038/s41388-019-0683-z.CrossRefPubMed

63.

Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, et al. m (6) A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nature Cell Biol. 2018;20:1074–83. https://doi.org/10.1038/s41556-018-0174-4.CrossRefPubMed

64.

Liu X, Qin J, Gao T, Li C, He B, Pan B, et al. YTHDF1 facilitates the progression of hepatocellular carcinoma by promoting FZD5 mRNA translation in an m6A-dependent manner. Mol Ther Nucleic Acids. 2020;22:750–65. https://doi.org/10.1016/j.omtn.2020.09.036.CrossRefPubMedPubMedCentral

65.

Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.CAN-20-0066.

66.

Liu L, Wang J, Sun G, Wu Q, Ma J, Zhang X, et al. m (6) A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma. Mol Cancer. 2019;18:188. https://doi.org/10.1186/s12943-019-1119-7.CrossRefPubMedPubMedCentral

67.

Wang K, Jiang L, Zhang Y, Chen C. Progression of thyroid carcinoma is promoted by the m6A methyltransferase METTL3 through regulating m (6) A methylation on TCF1. OncoTargets Ther. 2020;13:1605–12. https://doi.org/10.2147/ott.S234751.CrossRef

68.

Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019;442:252–61. https://doi.org/10.1016/j.canlet.2018.11.006.CrossRefPubMed

69.

Xie JW, Huang XB, Chen QY, Ma YB, Zhao YJ, Liu LC, et al. m (6) A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. Mol Cancer. 2020;19:114. https://doi.org/10.1186/s12943-020-01223-4.CrossRefPubMedPubMedCentral

70.

Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, et al. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol. 2020;14:373–86. https://doi.org/10.1002/1878-0261.12593.CrossRefPubMed

71.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m (6) A-dependent translation control. Nature. 2017;552:126–31. https://doi.org/10.1038/nature24678.CrossRefPubMedPubMedCentral

72.

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m (6) A Modification. Cell Stem Cell. 2018;22:191–205.e9. https://doi.org/10.1016/j.stem.2017.11.016.CrossRefPubMed

73.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m (6) A/MYC/CEBPA Signaling. Cell. 2018;172:90–105.e23. https://doi.org/10.1016/j.cell.2017.11.031.CrossRefPubMed

74.

Yue C, Chen J, Li Z, Li L, Chen J, Guo Y. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis. J Exper Clin Cancer Res. 2020;39:240. https://doi.org/10.1186/s13046-020-01731-7.CrossRef

75.

Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, et al. RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell. 2020. https://doi.org/10.1016/j.stem.2020.04.009.

76.

Xiang S, Liang X, Yin S, Liu J, Xiang Z. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. Am J Transl Res. 2020;12:1789–806.PubMedPubMedCentral

77.

Gao Q, Zheng J, Ni Z, Sun P, Yang C, Cheng M, et al. The m (6) A methylation-regulated AFF4 promotes self-renewal of bladder Cancer stem cells. Stem Cells Int. 2020;2020:8849218. https://doi.org/10.1155/2020/8849218.CrossRefPubMedPubMedCentral

78.

Zhu P, He F, Hou Y, Tu G, Li Q, Jin T, et al. A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability. Oncogene. 2021. https://doi.org/10.1038/s41388-020-01638-9.

79.

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N (6)-methyladenosine (m (6) A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369–76. https://doi.org/10.1038/nm.4416.CrossRefPubMedPubMedCentral

80.

Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:110. https://doi.org/10.1186/s12943-019-1036-9.CrossRefPubMedPubMedCentral

81.

Li F, Yi Y, Miao Y, Long W, Long T, Chen S, et al. N (6)-Methyladenosine modulates nonsense-mediated mRNA decay in human Glioblastoma. Cancer Res. 2019;79:5785–98. https://doi.org/10.1158/0008-5472.Can-18-2868.CrossRefPubMedPubMedCentral

82.

Zhou L, Yang C, Zhang N, Zhang X, Zhao T, Yu J. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2. Biomed Pharmacother. 2020;125:109964. https://doi.org/10.1016/j.biopha.2020.109964.CrossRefPubMed

83.

Xu J, Chen Q, Tian K, Liang R, Chen T, Gong A, et al. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation. Oncol Rep. 2020;44:973–86. https://doi.org/10.3892/or.2020.7665.CrossRefPubMedPubMedCentral

84.

Tian J, Ying P, Ke J, Zhu Y, Yang Y, Gong Y, et al. ANKLE1 N (6) -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability. Int J Cancer. 2020;146:3281–93. https://doi.org/10.1002/ijc.32677.CrossRefPubMed

85.

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N-6-Methyladenosine RNA Demethylase. Cancer Cell. 2017;31:127–41. https://doi.org/10.1016/j.ccell.2016.11.017.CrossRefPubMed

86.

Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18:46. https://doi.org/10.1186/s12943-019-1004-4.CrossRefPubMedPubMedCentral

87.

Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. m (6) A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell. 2017;31:591–606.e6. https://doi.org/10.1016/j.ccell.2017.02.013.CrossRefPubMedPubMedCentral

88.

Zhang X, Wang F, Wang Z, Yang X, Yu H, Si S, et al. ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m (6) A-dependent manner. Ann Transl Med. 2020;8:646. https://doi.org/10.21037/atm-20-3079.CrossRefPubMedPubMedCentral

89.

Ban Y, Tan P, Cai J, Li J, Hu M, Zhou Y, et al. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020;14:1282–96. https://doi.org/10.1002/1878-0261.12676.CrossRefPubMedPubMedCentral

90.

Wang J, Ding W, Xu Y, Tao E, Mo M, Xu W, et al. Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. Aging. 2020;12:4558–72. https://doi.org/10.18632/aging.102911.CrossRefPubMedPubMedCentral

91.

Barros-Silva D, Lobo J, Guimaraes-Teixeira C, Carneiro I, Oliveira J, Martens-Uzunova ES, et al. VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers. 2020;12. https://doi.org/10.3390/cancers12040771.

92.

Hu X, Peng WX, Zhou H, Jiang J, Zhou X, Huang D, et al. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. Cell Death Diff. 2020;27:1782–94. https://doi.org/10.1038/s41418-019-0461-z.CrossRef

93.

Chen S, Zhou L, Wang Y. ALKBH5-mediated m (6) A demethylation of lncRNA PVT1 plays an oncogenic role in osteosarcoma. Cancer Cell Int. 2020;20:34. https://doi.org/10.1186/s12935-020-1105-6.CrossRefPubMedPubMedCentral

94.

Liu H, Xu Y, Yao B, Sui T, Lai L, Li Z. A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR. Cell Death Dis. 2020;11:613. https://doi.org/10.1038/s41419-020-02833-y.CrossRefPubMedPubMedCentral

95.

Dai S, Mo Y, Wang Y, Xiang B, Liao Q, Zhou M, et al. Chronic stress promotes Cancer development. Front Oncol. 2020;10:1492. https://doi.org/10.3389/fonc.2020.01492.CrossRefPubMedPubMedCentral

96.

Ge J, Wang J, Wang H, Jiang X, Liao Q, Gong Q, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11:932–9. https://doi.org/10.7150/jca.33105.CrossRefPubMedPubMedCentral

97.

Wang D, Tang L, Wu Y, Fan C, Zhang S, Xiang B, et al. Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci. 2020;77:2949–58. https://doi.org/10.1007/s00018-020-03469-z.CrossRefPubMed

98.

Wei J, Wu C, Meng H, Li M, Niu W, Zhan Y, et al. The biogenesis and roles of extrachromosomal oncogene involved in carcinogenesis and evolution. Am J Cancer Res. 2020;10:3532–50.PubMedPubMedCentral

99.

Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng X, et al. Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. Mol Cancer. 2020;19:22. https://doi.org/10.1186/s12943-020-1147-3.CrossRefPubMedPubMedCentral

100.

Xiao L, Wei F, Liang F, Li Q, Deng H, Tan S, et al. TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing. Carcinogenesis. 2019;40:819–27. https://doi.org/10.1093/carcin/bgz095.CrossRefPubMed

101.

Yi M, Tan Y, Wang L, Cai J, Li X, Zeng Z, et al. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development. Cell Mol Life Sci. 2020;77:4325–46. https://doi.org/10.1007/s00018-020-03539-2.CrossRefPubMedPubMedCentral

102.

Wang H, Xu B, Shi J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene. 2020;722:144076. https://doi.org/10.1016/j.gene.2019.144076.CrossRefPubMed

103.

He H, Wu W, Sun Z, Chai L. MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m (6) A-caused stabilization of SEC62. Biochem Biophys Res Commun. 2019;517:581–7. https://doi.org/10.1016/j.bbrc.2019.07.058.CrossRefPubMed

104.

Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, et al. Targeting the RNA m (6) A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. Cell Stem Cell. 2019;25:137–48.e6. https://doi.org/10.1016/j.stem.2019.03.021.CrossRefPubMedPubMedCentral

105.

Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M, et al. m (6) A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018;9:1169. https://doi.org/10.1038/s41419-018-1224-3.CrossRefPubMedPubMedCentral

106.

Cai J, Yang F, Zhan H, Situ J, Li W, Mao Y, et al. RNA m (6) A methyltransferase METTL3 promotes the growth of prostate Cancer by regulating hedgehog pathway. OncoTargets Ther. 2019;12:9143–52. https://doi.org/10.2147/ott.S226796.CrossRef

107.

Bo H, Fan L, Gong Z, Liu Z, Shi L, Guo C, et al. Upregulation and hypomethylation of lncRNA AFAP1-AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. Oncol Rep. 2019;41:2431–9. https://doi.org/10.3892/or.2019.7027.CrossRefPubMed

108.

Chen S, Youhong T, Tan Y, He Y, Ban Y, Cai J, et al. EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2. Carcinogenesis. 2020;41:863–4. https://doi.org/10.1093/carcin/bgaa023.CrossRefPubMedPubMedCentral

109.

Deng X, Xiong W, Jiang X, Zhang S, Li Z, Zhou Y, et al. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020;11:945. https://doi.org/10.1038/s41419-020-03147-9.CrossRefPubMedPubMedCentral

110.

Fan C, Qu H, Xiong F, Tang Y, Tang T, Zhang L, et al. CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling. Cancer Lett. 2021;496:41–56. https://doi.org/10.1016/j.canlet.2020.09.006.CrossRefPubMed

111.

Tang T, Yang L, Cao Y, Wang M, Zhang S, Gong Z, et al. LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma. Mol Oncol. 2020;14:2251–70. https://doi.org/10.1002/1878-0261.12703.CrossRefPubMedPubMedCentral

112.

Wu Y, Wang D, Wei F, Xiong F, Zhang S, Gong Z, et al. EBV-miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1. FASEB J. 2020;34:16205–23. https://doi.org/10.1096/fj.202001508R.CrossRefPubMed

113.

Zhu K, Li P, Mo Y, Wang J, Jiang X, Ge J, et al. Neutrophils: accomplices in metastasis. Cancer Lett. 2020;492:11–20. https://doi.org/10.1016/j.canlet.2020.07.028.CrossRefPubMed

114.

Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, et al. Excessive miR-25-3p maturation via N (6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nature Commun. 2019;10:1858. https://doi.org/10.1038/s41467-019-09712-x.CrossRef

115.

Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19:106. https://doi.org/10.1186/s12943-020-01220-7.CrossRefPubMedPubMedCentral

116.

Li J, Xie H, Ying Y, Chen H, Yan H, He L, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19:152. https://doi.org/10.1186/s12943-020-01267-6.CrossRefPubMedPubMedCentral

117.

Peng W, Li J, Chen R, Gu Q, Yang P, Qian W, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway. J Exper Clin Cancer Res. 2019;38:393. https://doi.org/10.1186/s13046-019-1408-4.CrossRef

118.

Gong D, Zhang J, Chen Y, Xu Y, Ma J, Hu G, et al. The m (6) A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca (2+) influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway. J Exper Clin Cancer Res. 2019;38:233. https://doi.org/10.1186/s13046-019-1223-y.CrossRef

119.

Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m (6) A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12:135. https://doi.org/10.1186/s13045-019-0830-6.CrossRefPubMedPubMedCentral

120.

Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m (6) A reader YTHDF3. Mol Cancer. 2019;18:143. https://doi.org/10.1186/s12943-019-1079-y.CrossRefPubMedPubMedCentral

121.

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exper Clin Cancer Res. 2020;39:204. https://doi.org/10.1186/s13046-020-01709-5.CrossRef

122.

Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20:7. https://doi.org/10.1186/s12943-020-01288-1.CrossRefPubMedPubMedCentral

123.

Wu Y, Wei F, Tang L, Liao Q, Wang H, Shi L, et al. Herpesvirus acts with the cytoskeleton and promotes cancer progression. J Cancer. 2019;10:2185–93. https://doi.org/10.7150/jca.30222.CrossRefPubMedPubMedCentral

124.

Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, et al. Cross-talk among writers, readers, and erasers of m (6) A regulates cancer growth and progression. Sci Adv. 2018;4:eaar8263. https://doi.org/10.1126/sciadv.aar8263.CrossRefPubMedPubMedCentral

125.

Li J, Chen F, Peng Y, Lv Z, Lin X, Chen Z, et al. N6-Methyladenosine Regulates the Expression and Secretion of TGFβ1 to Affect the Epithelial-Mesenchymal Transition of Cancer Cells. Cells. 2020;9. https://doi.org/10.3390/cells9020296.

126.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, et al. m (6) A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020;19:40. https://doi.org/10.1186/s12943-020-01161-1.CrossRefPubMedPubMedCentral

127.

Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, et al. RNA m (6) A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of snail. Nat Commun. 2019;10:2065. https://doi.org/10.1038/s41467-019-09865-9.CrossRefPubMedPubMedCentral

128.

Xu H, Wang H, Zhao W, Fu S, Li Y, Ni W, et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating snail mRNA homeostasis in hepatocellular carcinoma. Theranostics. 2020;10:5671–86. https://doi.org/10.7150/thno.42539.CrossRefPubMedPubMedCentral

129.

Yu X, Zhao H, Cao Z. The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA. Minerva medica. 2020. https://doi.org/10.23736/s0026-4806.20.06653-7.

130.

Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F, et al. m (6) A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019;18:87. https://doi.org/10.1186/s12943-019-1014-2.CrossRefPubMedPubMedCentral

131.

Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;18:142. https://doi.org/10.1186/s12943-019-1065-4.CrossRefPubMedPubMedCentral

132.

Cheng C, Wu Y, Xiao T, Xue J, Sun J, Xia H, et al. METTL3-mediated m (6) A modification of ZBTB4 mRNA is involved in the smoking-induced EMT in cancer of the lung. Mol Ther Nucleic Acids. 2021;23:487–500. https://doi.org/10.1016/j.omtn.2020.12.001.CrossRefPubMed

133.

Jin H, Ying X, Que B, Wang X, Chao Y, Zhang H, et al. N (6)-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine. 2019;47:195–207. https://doi.org/10.1016/j.ebiom.2019.07.068.CrossRefPubMedPubMedCentral

134.

Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL, Lv JW, et al. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res. 2019;79:4612–26. https://doi.org/10.1158/0008-5472.Can-19-0799.CrossRefPubMed

135.

Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an m (6) A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112. https://doi.org/10.1186/s12943-019-1038-7.CrossRefPubMedPubMedCentral

136.

Xie H, Li J, Ying Y, Yan H, Jin K, Ma X, et al. METTL3/YTHDF2 m (6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. J Cell Mol Med. 2020;24:4092–104. https://doi.org/10.1111/jcmm.15063.CrossRefPubMedPubMedCentral

137.

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020;39:4507–18. https://doi.org/10.1038/s41388-020-1303-7.CrossRefPubMed

138.

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816–31. https://doi.org/10.1093/nar/gkaa048.CrossRefPubMedPubMedCentral

139.

Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, et al. YTHDF3 Induces the Translation of m (6) A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell. 2020;38:857–71.e7. https://doi.org/10.1016/j.ccell.2020.10.004.CrossRefPubMedPubMedCentral

140.

Wang M, Liu J, Zhao Y, He R, Xu X, Guo X, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N (6) adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020;19:130. https://doi.org/10.1186/s12943-020-01249-8.CrossRefPubMedPubMedCentral

141.

Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, et al. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m (6) A-guided epigenetic inhibition of LYPD1. Mol Cancer. 2020;19:123. https://doi.org/10.1186/s12943-020-01239-w.CrossRefPubMedPubMedCentral

142.

Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18:186. https://doi.org/10.1186/s12943-019-1106-z.CrossRefPubMedPubMedCentral

143.

Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N (6) -methyladenosine-dependent primary MicroRNA processing. Hepatology (Baltimore, Md). 2017;65:529–43. https://doi.org/10.1002/hep.28885.CrossRef

144.

Chen X, Xu M, Xu X, Zeng K, Liu X, Sun L, et al. METTL14 suppresses CRC progression via regulating N6-Methyladenosine-dependent primary miR-375 processing. Mol Ther. 2020;28:599–612. https://doi.org/10.1016/j.ymthe.2019.11.016.CrossRefPubMed

145.

Yang X, Zhang S, He C, Xue P, Zhang L, He Z, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19:46. https://doi.org/10.1186/s12943-020-1146-4.CrossRefPubMedPubMedCentral

146.

Wen S, Wei Y, Zen C, Xiong W, Niu Y, Zhao Y. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Mol Cancer. 2020;19:171. https://doi.org/10.1186/s12943-020-01293-4.CrossRefPubMedPubMedCentral

147.

Hou P, Meng S, Li M, Lin T, Chu S, Li Z, et al. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. J Exper Clin Cancer Res. 2021;40:52. https://doi.org/10.1186/s13046-021-01857-2.CrossRef

148.

Wang X, Liu C, Zhang S, Yan H, Zhang L, Jiang A, et al. N (6)-methyladenosine modification of MALAT1 promotes metastasis via reshaping nuclear speckles. Dev Cell. 2021. https://doi.org/10.1016/j.devcel.2021.01.015.

149.

Fan C, Zhang S, Gong Z, Li X, Xiang B, Deng H, et al. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci. 2020. https://doi.org/10.1007/s11427-019-1735-4.

150.

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10. https://doi.org/10.1186/s12943-018-0928-4.CrossRefPubMedPubMedCentral

151.

Mo Y, Wang Y, Zhang L, Yang L, Zhou M, Li X, et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer. 2019;10:3789–97. https://doi.org/10.7150/jca.31166.CrossRefPubMedPubMedCentral

152.

Wang YA, Li XL, Mo YZ, Fan CM, Tang L, Xiong F, et al. Effects of tumor metabolic microenvironment on regulatory T cells. Mol Cancer. 2018;17:168. https://doi.org/10.1186/s12943-018-0913-y.CrossRefPubMedPubMedCentral

153.

Wei F, Wang D, Wei J, Tang N, Tang L, Xiong F, et al. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell Mol Life Sci. 2021;78:173–93. https://doi.org/10.1007/s00018-020-03581-0.CrossRefPubMed

154.

Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J, et al. RNA N (6)-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m (6) A-GLUT1-mTORC1 Axis and Is a Therapeutic Target. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.11.013.

155.

Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, et al. m (6) A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020;19:72. https://doi.org/10.1186/s12943-020-01190-w.CrossRefPubMedPubMedCentral

156.

Qing Y, Dong L, Gao L, Li C, Li Y, Han L, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m (6) A/PFKP/LDHB axis. Mol Cell. 2021. https://doi.org/10.1016/j.molcel.2020.12.026.

157.

Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen YX, et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18:174. https://doi.org/10.1186/s12943-019-1105-0.CrossRefPubMedPubMedCentral

158.

Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated m (6) A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69:1193–205. https://doi.org/10.1136/gutjnl-2019-319639.CrossRefPubMed

159.

Li Z, Peng Y, Li J, Chen Z, Chen F, Tu J, et al. N (6)-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat Commun. 2020;11:2578. https://doi.org/10.1038/s41467-020-16306-5.CrossRefPubMedPubMedCentral

160.

Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J, et al. m (6) A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2020. https://doi.org/10.1002/jcp.30023.

161.

Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J, et al. m (6) A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236:2649–58. https://doi.org/10.1002/jcp.30023.CrossRefPubMed

162.

Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important role of FTO in the survival of rare Panresistant triple-negative inflammatory breast Cancer cells facing a severe metabolic challenge. PloS one. 2016;11:e015e9072. https://doi.org/10.1371/journal.pone.0159072.CrossRef

163.

Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43:373–84. https://doi.org/10.1093/nar/gku1276.CrossRefPubMed

164.

Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, et al. m (6) A RNA methylation regulates the self-renewal and tumorigenesis of Glioblastoma stem cells. Cell Rep. 2017;18:2622–34. https://doi.org/10.1016/j.celrep.2017.02.059.CrossRefPubMedPubMedCentral

165.

Xiao L, Li X, Mu Z, Zhou J, Zhou P, Xie C, et al. FTO inhibition enhances the anti-tumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.Can-20-0132.

166.

Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019;35:677–91.e10. https://doi.org/10.1016/j.ccell.2019.03.006.CrossRefPubMedPubMedCentral

167.

Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020;38:79–96.e11. https://doi.org/10.1016/j.ccell.2020.04.017.CrossRefPubMedPubMedCentral

168.

Wang L, Song C, Wang N, Li S, Liu Q, Sun Z, et al. NADP modulates RNA m (6) A methylation and adipogenesis via enhancing FTO activity. Nat Chem Biol. 2020. https://doi.org/10.1038/s41589-020-0601-2.

169.

Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q, et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in Glioblastoma stem cells. Cancer Discov. 2021;11:480–99. https://doi.org/10.1158/2159-8290.Cd-20-0331.CrossRefPubMed

170.

Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18:29. https://doi.org/10.1186/s12943-019-0956-8.CrossRefPubMedPubMedCentral

171.

Fan C, Wang J, Tang Y, Zhang S, Xiong F, Guo C, et al. Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers. BMC Cancer. 2020;20:917. https://doi.org/10.1186/s12885-020-07408-w.CrossRefPubMedPubMedCentral

172.

Fan CM, Wang JP, Tang YY, Zhao J, He SY, Xiong F, et al. circMAN1A2 could serve as a novel serum biomarker for malignant tumors. Cancer Sci. 2019;110:2180–8. https://doi.org/10.1111/cas.14034.CrossRefPubMedPubMedCentral

173.

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128. https://doi.org/10.1186/s12943-019-1055-6.CrossRefPubMedPubMedCentral

174.

Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:19. https://doi.org/10.1186/s12943-020-1144-6.CrossRefPubMedPubMedCentral

175.

Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7. https://doi.org/10.1007/s11427-018-9461-5.CrossRefPubMed

176.

Xiong F, Deng S, Huang HB, Li XY, Zhang WL, Liao QJ, et al. Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. Chin Med J. 2019;132:749–52. https://doi.org/10.1097/cm9.0000000000000132.CrossRefPubMedPubMedCentral

177.

Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, et al. Single-cell RNA sequencing in cancer research. J Exper Clin Cancer Res. 2021;40:81. https://doi.org/10.1186/s13046-021-01874-1.CrossRef

178.

Zhao J, Guo C, Xiong F, Yu J, Ge J, Wang H, et al. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma. Cancer Lett. 2020;477:131–43. https://doi.org/10.1016/j.canlet.2020.02.010.CrossRefPubMed

179.

Hao CC, Xu CY, Zhao XY, Luo JN, Wang G, Zhao LH, et al. Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma. J Exper Clin Cancer Res. 2020;39:256. https://doi.org/10.1186/s13046-020-01772-y.CrossRef

180.

Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol Carcinog. 2018;57:590–7. https://doi.org/10.1002/mc.22782.CrossRefPubMed

181.

Kowalski-Chauvel A, Lacore MG, Arnauduc F, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, et al. The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells. Cancers. 2020;13. https://doi.org/10.3390/cancers13010040.

182.

Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52:621–9. https://doi.org/10.3892/ijo.2017.4219.CrossRefPubMed

183.

Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, et al. Essential role of METTL3-mediated m (6) A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37:522–33. https://doi.org/10.1038/onc.2017.351.CrossRefPubMed

184.

He JJ, Li Z, Rong ZX, Gao J, Mu Y, Guan YD, et al. m (6) A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis. Front Oncol. 2020;10:1166. https://doi.org/10.3389/fonc.2020.01166.CrossRefPubMedPubMedCentral

185.

Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, et al. A dynamic N (6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018;28:1062–76. https://doi.org/10.1038/s41422-018-0097-4.CrossRefPubMedPubMedCentral

186.

Uddin MB, Roy KR, Hosain SB, Khiste SK, Hill RA, Jois SD, et al. An N (6)-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem Pharmacol. 2019;160:134–45. https://doi.org/10.1016/j.bcp.2018.12.014.CrossRefPubMed

187.

Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m (6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181. https://doi.org/10.15252/embj.2019103181.CrossRefPubMedPubMedCentral

188.

Zhou T, Li S, Xiang D, Liu J, Sun W, Cui X, et al. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther. 2020;5:296. https://doi.org/10.1038/s41392-020-00299-0.CrossRefPubMedPubMedCentral

189.

Xu J, Wan Z, Tang M, Lin Z, Jiang S, Ji L, et al. N (6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer. 2020;19:163. https://doi.org/10.1186/s12943-020-01281-8.CrossRefPubMedPubMedCentral

190.

Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N (6)-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79:2812–20. https://doi.org/10.1158/0008-5472.Can-18-3592.CrossRefPubMedPubMedCentral

191.

Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, et al. m (6) A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020;19:3. https://doi.org/10.1186/s12943-019-1128-6.CrossRefPubMedPubMedCentral

192.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m (6) A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270–4. https://doi.org/10.1038/s41586-019-0916-x.CrossRefPubMedPubMedCentral

193.

Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, et al. m (6) A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10:2782. https://doi.org/10.1038/s41467-019-10669-0.CrossRefPubMedPubMedCentral

194.

Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117:20159–70. https://doi.org/10.1073/pnas.1918986117.CrossRefPubMedPubMedCentral

195.

Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, et al. m (6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39:e104514. https://doi.org/10.15252/embj.2020104514.CrossRefPubMedPubMedCentral

196.

Wilson C, Chen PJ, Miao Z, Liu DR. Programmable m (6) A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat Biotechnol. 2020;https://doi.org/10.1038/s41587-020-0572-6

197.

Li J, Chen Z, Chen F, Xie G, Ling Y, Peng Y, et al. Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res. 2020;48:5684–94. https://doi.org/10.1093/nar/gkaa269.CrossRefPubMedPubMedCentral

198.

Parker MT, Knop K, Sherwood AV, Schurch NJ, Mackinnon K, Gould PD, et al. Nanopore direct RNA sequencing maps the complexity of Arabidopsis mRNA processing and m (6) A modification. Elife. 2020;9. https://doi.org/10.7554/eLife.49658.

199.

Song T, Yang Y, Wei H, Xie X, Lu J, Zeng Q, et al. Zfp217 mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation. Nucleic Acids Res. 2019;47:6130–44. https://doi.org/10.1093/nar/gkz312.CrossRefPubMedPubMedCentral

200.

Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, et al. Histone H3 trimethylation at lysine 36 guides m (6) A RNA modification co-transcriptionally. Nature. 2019;567:414–9. https://doi.org/10.1038/s41586-019-1016-7.CrossRefPubMedPubMedCentral

201.

An S, Huang W, Huang X, Cun Y, Cheng W, Sun X, et al. Integrative network analysis identifies cell-specific trans regulators of m6A. Nucleic Acids Res. 2020;48:1715–29. https://doi.org/10.1093/nar/gkz1206.CrossRefPubMedPubMedCentral

202.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

203.

Abakir A, Giles TC, Cristini A, Foster JM, Dai N, Starczak M, et al. N (6)-methyladenosine regulates the stability of RNA:DNA hybrids in human cells. Nat Genet. 2020;52:48–55. https://doi.org/10.1038/s41588-019-0549-x.CrossRefPubMed

204.

Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y, et al. METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. Mol Cell. 2020;79:425–42.e7. https://doi.org/10.1016/j.molcel.2020.06.017.CrossRefPubMed

205.

Wang H, Deng Q, Lv Z, Ling Y, Hou X, Chen Z, et al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Mol Cancer. 2019;18:181. https://doi.org/10.1186/s12943-019-1108-x.CrossRefPubMedPubMedCentral

206.

Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z, et al. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer. 2019;18:163. https://doi.org/10.1186/s12943-019-1082-3.CrossRefPubMedPubMedCentral

207.

Li Y, Xia L, Tan K, Ye X, Zuo Z, Li M, et al. N (6)-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat Genet. 2020;52:870–7. https://doi.org/10.1038/s41588-020-0677-3.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Fibroblast growth factor receptor fusions in cancer: opportunities and challenges

ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma

Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC

Neutrophil extracellular traps in cancer: not only catching microbes

IκBα targeting promotes oxidative stress-dependent cell death

Keynote webinar | Spotlight on antibody–drug conjugates in cancer